Organization formed to further interoperability

A new provider led, not-for-profit, multistakeholder organization aims to foster a collaborative industry-wide initiative for an open services oriented architecture (SOA)-based platform, a next-generation technology model and multi-vendor restful web services modeled against HL7 FHIR and CIMI/CEM based profiles.

The Healthcare Services Platform Consortium (HSPC) received commitment from Salt Lake City-based Intermountain Healthcare and LSU Health Care Services Division, a Baton Rouge-based academic healthcare organization, as founding members.

HSPC also appointed Stanley M. Huff, MD, CMIO at Intermountain Healthcare, as chairman of the board of directors, and Oscar Diaz, former vice president and general manager of Harris Healthcare Solutions, as CEO.

The consortium’s primary objective, according to a release, is to leverage hard-won work on SOA at the Veterans Administration, Intermountain, Arizona State University, Regenstrief Institute and other organizations to accelerate application development through an open-standards-based, SOA platform and create a new marketplace for semantic, native interoperability in healthcare. HSPC will support an "app store" model which will support common services and models that vendors can use to shorten development lifecycles.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.